6,800
Participants
Start Date
March 4, 2024
Primary Completion Date
October 1, 2026
Study Completion Date
December 1, 2026
Bismuth-based quadruple therapy
"Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
Levofloxacin-based quadruple therapy
"In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
Standard triple therapy
"Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg."
Levofloxacin-based triple
"Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg"
RECRUITING
National Institute of Public Health, Slovenia, Ljubljana
RECRUITING
University Hospital Centre Zagreb, Zagreb
RECRUITING
Clinical Hospital Center Rijeka, Rijeka
RECRUITING
Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca
RECRUITING
Beacon Hospital, Dublin
NOT_YET_RECRUITING
Clinical and Preventive Medicine of the University of Latvia, Riga
RECRUITING
Wroclaw Medical University, Wroclaw
Collaborators (2)
Clinical Hospital Center Rijeka
OTHER
Clinical Hospital Centre Zagreb
OTHER
Beacon Hospital
OTHER
Wroclaw Medical University
OTHER
Iuliu Hatieganu University of Medicine and Pharmacy
OTHER
National Institute of Public Health, Slovenia
OTHER_GOV
University of Latvia
OTHER